{"id":"W3217079453","doi":"10.1016/j.annonc.2021.11.018","title":"Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; Vifor Pharma; AbbVie; Roche; Pfizer","keywords":"Carboplatin; Veliparib; Medicine; Internal medicine; Placebo; Hazard ratio; PARP inhibitor; Paclitaxel; Oncology; Breast cancer; Interim analysis; Clinical endpoint; Chemotherapy; Randomized controlled trial; Urology; Cancer; Confidence interval; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432293,0.001020164,0.002182577,0.0002884706,0.0003477733,0.001401825,0.0005952806,0.0008524923,0.001664375],"category_scores_gemma":[0.001570042,0.0004513298,0.002047089,0.0004843931,0.0006459856,0.0008034353,0.0003558201,0.002489608,0.0003521103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009846099,"about_ca_system_score_gemma":0.00116117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006876123,"about_ca_topic_score_gemma":0.002693488,"domain_scores_codex":[0.9990487,0.0005504586,0.00005586118,0.0001598195,0.00006479467,0.0001204623],"domain_scores_gemma":[0.999022,0.0002753068,0.0002365333,0.0001005236,0.00004974684,0.0003158176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9262121,0.005461957,0.01083343,0.0005927098,0.003459114,0.0001624195,0.0001263973,0.001651495,0.007497565,0.0002030695,0.002037668,0.04176193],"study_design_scores_gemma":[0.7971671,0.1541386,0.03769343,0.0001519162,0.003179534,0.0003644988,0.0001025116,0.001762084,0.001409981,0.0005533473,0.003415864,0.00006111322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896876,0.006033768,0.0003112024,0.0006736174,0.0001264775,0.0006296247,0.000830491,0.00003966218,0.001667547],"genre_scores_gemma":[0.993655,0.002038938,0.0005930677,0.0007456374,0.0001628435,0.000528047,0.001357576,0.00001289401,0.0009059542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002432293,"threshold_uncertainty_score":0.01286334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1201078369942618,"score_gpt":0.4370745556466084,"score_spread":0.3169667186523466,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}